Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 5;65(6):2401349.
doi: 10.1183/13993003.01349-2024. Print 2025 Jun.

Protein biomarkers of interstitial lung abnormalities in relatives of patients with pulmonary fibrosis

Affiliations

Protein biomarkers of interstitial lung abnormalities in relatives of patients with pulmonary fibrosis

Jonathan A Rose et al. Eur Respir J. .

Abstract

Rationale: First-degree relatives of patients with pulmonary fibrosis (referred to here as relatives) are at high risk for interstitial lung abnormalities (ILA), highlighting the need for biomarkers for risk prediction. We aimed to identify blood proteins associated with and predictive of ILA among relatives of patients with pulmonary fibrosis.

Methods: Relatives enrolled in two independent cohorts had protein levels measured using an aptamer-based proteomic platform. ILA were assessed with computed tomography scans as per Fleischner Society recommendations. Protein associations with ILA were assessed using regression. Significant proteins were used with clinical variables to detect ILA.

Results: Of 237 relatives from two independent cohorts, 26% had ILA. Seven proteins were associated with ILA in the discovery cohort after false discovery rate adjustment, and all remained significant after adjusting for age, gender and smoking status. Six of the seven proteins were significantly associated in the validation cohort, including growth differentiation factor 15, surfactant protein D and surfactant protein B. In a multivariable model, six proteins combined with basic demographics in the discovery cohort had an area under the curve of 0.92 (0.88 in the validation cohort). Least absolute shrinkage and selection operator modelling identified three proteins and age as predictors, with an area under the curve of 0.89 in the validation cohort. When applied to the combined cohorts, this simple model would reduce the need for computed tomography imaging in one of every three relatives screened.

Conclusion: Peripheral blood proteins are associated with ILA in relatives of patients with pulmonary fibrosis and can be used to detect them. Our findings demonstrate the potential use of blood biomarkers in this high-risk group and suggest molecular targets for future investigation.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: G.T. Axelsson reports travel support for meetings from Boehringer Ingelheim. M.B. Rice reports lecture honoraria paid by University of Southern California, University of Utah, New York University, University of North Carolina, University of Vermont and Northwestern University; payment from Conservation Law Foundation for providing an expert opinion; support for American Thoracic Society (ATS) registration in 2022 due to a role as programme committee chair; leadership of the ATS Environmental Health Policy committee until May 2020; programme committee chair 2022–2023 for the Environmental, Occupational and Population Health (EOPH) assembly of ATS; and chair-elect of the EOPH assembly of ATS 2024. J.S. Lee reports grants from Boehringer Ingelheim; consulting fees from Blade, Avalyn, Boehringer Ingelheim, United Therapeutics, AstraZeneca, Elima and Eleven P15; participation on a data safety monitoring board or advisory board for United Therapeutics (TETON trial) and Avalyn Pharma (ATLAS trial); acting as a senior medical advisor for the Pulmonary Fibrosis Foundation; and receiving a research gift from Pliant Therapeutics. H. Hatabu reports grants from Canon Medical Systems Inc. and Konica Minolta Inc. and consulting fees from Boehringer Ingelheim and Canon Medical Systems Inc. B.A. Raby reports royalties from UpToDate as an editor. D.A. Schwartz reports consulting fees from Vertex and being a founder and chief scientific officer of Eleven P15, Inc., a company focused on the early diagnosis and treatment of pulmonary fibrosis. I.O. Rosas reports grants from Boehringer Ingelheim, Genentech and Roche; and participation on an advisory board for Boehringer Ingelheim, Avalyn Pharma and Structure Therapeutics. G.M. Hunninghake reports consulting fees from Boehringer Ingelheim and Gerson Lehrman Group, and lecture fees from Boehringer Ingelheim. The remaining authors have no potential conflicts of interest to disclose.

Figures

None
Overview of the study. AUC: area under the receiver operating characteristic curve; CT: computed tomography; GDF15: growth differentiation factor 15; ILA: interstitial lung abnormalities; SFTPB: surfactant protein B; SFTPD: surfactant protein D.
FIGURE 1
FIGURE 1
Discovery of single protein associations with interstitial lung abnormalities using univariable logistic regression models. CDCP1: CUB domain-containing protein 1; CLIC3: chloride intracellular channel 3; GALNS: galactosamine (N-acetyl)-6-sulfatase; GCHFR: GTP cyclohydrolase I feedback regulatory protein; GDF15: growth differentiation factor 15; ICAM5: intercellular adhesion molecule 5; MMP12: matrix metallopeptidase 12; NPW: neuropeptide W; PXDN: peroxidasin; RELT: RELT tumour necrosis factor receptor; SFN: stratifin; SFTPB: surfactant protein B; SFTPD: surfactant protein D; TIMP1: TIMP metallopeptidase inhibitor 1; TREM1: triggering receptor expressed on myeloid cells 1; WFDC2: WAP four-disulfide core domain protein 2.
FIGURE 2
FIGURE 2
Proteins and demographics for the detection of interstitial lung abnormalities (ILA). Receiver operating characteristic (ROC) curves and area under the ROC curves (AUC) for the detection of ILA. a) Logistic regression models were used in the Clinical Genetics and Screening for Pulmonary Fibrosis (CGS-PF) cohort with clinical data and/or the six proteins significantly associated with ILA as the training set. The multiprotein model with the six validated proteins was a significant improvement over the model with demographics alone (p=0.003). The final model with demographics and the six proteins had an AUC of 0.92. b) The models established in CGS-PF were then tested in the independent Colorado cohort. The final model with demographics and the six proteins had an AUC of 0.88.
FIGURE 3
FIGURE 3
Simplified model for the detection of interstitial lung abnormalities (ILA). Receiver operating characteristic (ROC) curves and area under the ROC curves (AUC) of the simplified model derived from machine learning for the detection of ILA. Variable selection using least absolute shrinkage and selection operator (LASSO) modelling of the discovery cohort gave four variables shown in the table inset with coefficients. These four variables were used in multivariable logistic regression for the detection of ILA in the discovery cohort (red curve). This model was then applied to the validation cohort to generate an estimate of ILA detection (blue curve) and gave an AUC of 0.89. A table of local maximas of the ROC curve from the validation cohort and corresponding test performance characteristics in the combined cohorts are shown in supplementary table E6. GDF15: growth differentiation factor 15; SFTPB: surfactant protein B; SFTPD: surfactant protein D.

Comment in

Similar articles

Cited by

References

    1. Rosas IO, Ren P, Avila NA, et al. Early interstitial lung disease in familial pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176: 698–705. doi: 10.1164/rccm.200702-254OC - DOI - PMC - PubMed
    1. Hunninghake GM, Quesada-Arias LD, Carmichael NE, et al. Interstitial lung disease in relatives of patients with pulmonary fibrosis. Am J Respir Crit Care Med 2020; 201: 1240–1248. doi: 10.1164/rccm.201908-1571OC - DOI - PMC - PubMed
    1. Salisbury ML, Hewlett JC, Ding G, et al. Development and progression of radiologic abnormalities in individuals at risk for familial interstitial lung disease. Am J Respir Crit Care Med 2020; 201: 1230–1239. doi: 10.1164/rccm.201909-1834OC - DOI - PMC - PubMed
    1. Rose JA, Planchart Ferretto MA, Maeda AH, et al. Progressive interstitial lung disease in relatives of patients with pulmonary fibrosis. Am J Respir Crit Care Med 2023; 207: 211–214. doi: 10.1164/rccm.202208-1470LE - DOI - PMC - PubMed
    1. Steele MP, Peljto AL, Mathai SK, et al. Incidence and progression of fibrotic lung disease in an at-risk cohort. Am J Respir Crit Care Med 2023; 207: 587–593. doi: 10.1164/rccm.202206-1075OC - DOI - PMC - PubMed